Iclaprim
| Title | Journal |
|---|---|
| Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. | Mayo Clinic proceedings 20120401 |
| Toward new therapeutics for skin and soft tissue infections: propargyl-linked antifolates are potent inhibitors of MRSA and Streptococcus pyogenes. | PloS one 20120101 |
| Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines. | Bioorganic & medicinal chemistry letters 20110915 |
| Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy. | Drug, healthcare and patient safety 20110101 |
| Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. | International journal of antimicrobial agents 20101101 |
| Mechanisms of resistance to antimicrobial drugs in pathogenic Gram-positive cocci. | Mini reviews in medicinal chemistry 20100901 |
| Enantioselective synthesis of iclaprim enantiomers--a versatile approach to 2-substituted chiral chromenes. | The Journal of organic chemistry 20100604 |
| [Update on antimicrobial chemotherapy]. | Medecine et maladies infectieuses 20100301 |
| Future treatment options for Gram-positive infections--looking ahead. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20091201 |
| New antimicrobial agents for methicillin-resistant Staphylococcus aureus. | Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine 20091201 |
| New treatments for methicillin-resistant Staphylococcus aureus. | Current opinion in critical care 20091001 |
| [New antibiotics: small or big advances?]. | Der Internist 20091001 |
| Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. | The Journal of infection 20090901 |
| Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. | Acta crystallographica. Section D, Biological crystallography 20090801 |
| Antimicrobial development in the era of emerging resistance. | Mini reviews in medicinal chemistry 20090701 |
| Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. | The Annals of pharmacotherapy 20090601 |
| Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. | The Journal of antimicrobial chemotherapy 20090401 |
| New antimicrobial molecules and new antibiotic strategies. | Seminars in respiratory and critical care medicine 20090401 |
| In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects. | Diagnostic microbiology and infectious disease 20090301 |
| Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections. | Future microbiology 20090301 |
| Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae. | The Journal of antimicrobial chemotherapy 20090201 |
| New antibiotics for healthcare-associated pneumonia. | Seminars in respiratory and critical care medicine 20090201 |
| Regulatory watch: Non-inferiority-trial discussions impact new drug applications. | Nature reviews. Drug discovery 20090101 |
| Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit. | Critical care (London, England) 20090101 |
| New antibiotics for antibiotic-resistant bacteria. | F1000 biology reports 20090101 |
| The determinants of the antibiotic resistance process. | Infection and drug resistance 20090101 |
| Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus. | Infection and drug resistance 20090101 |
| What's new and not so new on the antimicrobial horizon? | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20081201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20081001 |
| Investigational antimicrobial drugs for bloodstream infections. | Current opinion in investigational drugs (London, England : 2000) 20080801 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080601 |
| Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. | Current opinion in investigational drugs (London, England : 2000) 20080201 |
| Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. | Expert review of anti-infective therapy 20080201 |
| A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). | Therapeutics and clinical risk management 20080201 |
| Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. | Recent patents on anti-infective drug discovery 20080101 |
| [New antimicrobials against Gram-positive organisms]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| Current and novel antibiotics against resistant Gram-positive bacteria. | Infection and drug resistance 20080101 |
| Effect of human plasma on the antimicrobial activity of iclaprim in vitro. | The Journal of antimicrobial chemotherapy 20071201 |
| In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. | The Journal of antimicrobial chemotherapy 20071201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071201 |
| Activity of iclaprim against Legionella pneumophila. | The Journal of antimicrobial chemotherapy 20071001 |
| Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070915 |
| Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. | The Journal of antimicrobial chemotherapy 20070901 |
| Iclaprim. | Expert opinion on investigational drugs 20070901 |
| Investigational treatments for postoperative surgical site infections. | Expert opinion on investigational drugs 20070201 |
| Infections associated with orthopedic implants. | Current opinion in infectious diseases 20060801 |
| Antibacterial drug discovery and development--SRI's 11th Annual Summit. Antibacterial trends and current research. | IDrugs : the investigational drugs journal 20060601 |
| Dihydrofolate reductase inhibitors as antibacterial agents. | Biochemical pharmacology 20060330 |
| Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. | Current opinion in microbiology 20051001 |
| Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. | Bioorganic & medicinal chemistry letters 20031201 |